Canada Pension Plan Investment Board Boosts Holdings in Danaher Co. (NYSE:DHR)

Canada Pension Plan Investment Board boosted its position in Danaher Co. (NYSE:DHR) by 14.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,629,419 shares of the conglomerate’s stock after purchasing an additional 203,975 shares during the quarter. Canada Pension Plan Investment Board owned about 0.22% of Danaher worth $407,110,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in DHR. Cape Investment Advisory Inc. bought a new position in shares of Danaher in the 4th quarter worth $25,000. Tsfg LLC increased its holdings in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after buying an additional 88 shares during the last quarter. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher in the 2nd quarter worth $25,000. nVerses Capital LLC bought a new position in shares of Danaher in the 2nd quarter worth $25,000. Finally, Redmont Wealth Advisors LLC bought a new position in shares of Danaher in the 1st quarter worth $30,000. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 in the last three months. Company insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on DHR shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 target price on shares of Danaher in a report on Friday, September 6th. The Goldman Sachs Group increased their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Leerink Partners increased their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Jefferies Financial Group started coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 price target for the company. Finally, Evercore ISI dropped their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Seven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $278.94.

Danaher Trading Up 1.7 %

Shares of NYSE DHR opened at $276.43 on Friday. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The stock has a market cap of $204.75 billion, a P/E ratio of 46.85, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83. The firm has a 50-day moving average of $267.10 and a 200 day moving average of $257.03. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the company posted $2.05 EPS. Danaher’s revenue was down 2.9% on a year-over-year basis. As a group, sell-side analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.